Related references
Note: Only part of the references are listed.The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Carlos Zamora Atenza et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Phase II study of nivolumab and salvage nivolumab plus ipilimumab in treatment-naive patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Kathleen M. Mahoney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Barbara Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu et al.
FRONTIERS IN IMMUNOLOGY (2022)
The role of biomarkers in personalized immunotherapy
Kamya Sankar et al.
BIOMARKER RESEARCH (2022)
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
Tao Wang et al.
BIOMEDICINES (2022)
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte
Baojuan Han et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
Pei Huang et al.
FRONTIERS IN ONCOLOGY (2021)
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh et al.
SCIENTIFIC REPORTS (2021)
Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Guixiang Liao et al.
FRONTIERS IN ONCOLOGY (2021)
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
Devayani Machiraju et al.
ONCOIMMUNOLOGY (2021)
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
Carla Chiarucci et al.
CANCERS (2020)
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
Marine Cordonnier et al.
JOURNAL OF EXTRACELLULAR VESICLES (2020)
Soluble PD-L1 and Circulating CD8+PD-1+and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
G. Mazzaschi et al.
LUNG CANCER (2020)
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
Lorena Incorvaia et al.
ONCOIMMUNOLOGY (2020)
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
Ilaria Grazia Zizzari et al.
JOURNAL OF PERSONALIZED MEDICINE (2020)
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody
Shuji Murakami et al.
THORACIC CANCER (2020)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Identification and characterization of an alternative cancer-derived PD-L1 splice variant
Nadia B. Hassounah et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
Masahiro Takeuchi et al.
IMMUNOLOGY LETTERS (2018)
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors A meta-analysis
Wei Wei et al.
MEDICINE (2018)
Soluble immune checkpoints in cancer: production, function and biological significance
Daqian Gu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors
Ryan Gentzler et al.
IMMUNOTHERAPY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Soluble B7-H1: Differences in production between dendritic cells and T cells
Xavier Frigola et al.
IMMUNOLOGY LETTERS (2012)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Share Paper
